JPWO2020132269A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020132269A5 JPWO2020132269A5 JP2021531985A JP2021531985A JPWO2020132269A5 JP WO2020132269 A5 JPWO2020132269 A5 JP WO2020132269A5 JP 2021531985 A JP2021531985 A JP 2021531985A JP 2021531985 A JP2021531985 A JP 2021531985A JP WO2020132269 A5 JPWO2020132269 A5 JP WO2020132269A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- trifluoromethyl
- pyrazolo
- pyrimidine
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 substituted Chemical class 0.000 claims description 303
- 201000011510 cancer Diseases 0.000 claims description 171
- 125000000217 alkyl group Chemical group 0.000 claims description 135
- 150000001875 compounds Chemical class 0.000 claims description 95
- 102100011578 USP1 Human genes 0.000 claims description 89
- 101700060715 USP1 Proteins 0.000 claims description 89
- 230000002401 inhibitory effect Effects 0.000 claims description 78
- 239000003112 inhibitor Substances 0.000 claims description 76
- 150000003839 salts Chemical class 0.000 claims description 68
- 239000011780 sodium chloride Substances 0.000 claims description 68
- 239000012453 solvate Substances 0.000 claims description 68
- 230000035772 mutation Effects 0.000 claims description 66
- 125000001072 heteroaryl group Chemical group 0.000 claims description 39
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 38
- 125000003282 alkyl amino group Chemical group 0.000 claims description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims description 32
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 31
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 26
- 125000005843 halogen group Chemical group 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 claims description 24
- 125000004429 atoms Chemical group 0.000 claims description 22
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 20
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 16
- 125000003107 substituted aryl group Chemical group 0.000 claims description 15
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 14
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 14
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 14
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- FDDDEECHVMSUSB-UHFFFAOYSA-N Sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims description 9
- 125000005518 carboxamido group Chemical group 0.000 claims description 9
- 229960001663 sulfanilamide Drugs 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical class [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 125000001495 ethyl group Chemical class [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000001449 isopropyl group Chemical class [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 7
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 7
- 230000002950 deficient Effects 0.000 claims description 7
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 6
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 6
- 125000004414 alkyl thio group Chemical group 0.000 claims description 6
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 6
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 6
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- 238000004166 bioassay Methods 0.000 claims description 6
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 6
- 125000005191 hydroxyalkylamino group Chemical group 0.000 claims description 6
- 125000005358 mercaptoalkyl group Chemical group 0.000 claims description 6
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims description 4
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical class [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 230000009504 protein deubiquitination Effects 0.000 claims description 4
- 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 claims description 4
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- 231100000277 DNA damage Toxicity 0.000 claims description 3
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims description 3
- 238000002744 homologous recombination Methods 0.000 claims description 3
- 230000037361 pathway Effects 0.000 claims description 3
- 125000004214 1-pyrrolidinyl group Chemical class [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- NVBFHJWHLNUMCV-UHFFFAOYSA-N Sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 claims description 2
- 125000004422 alkyl sulphonamide group Chemical group 0.000 claims description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 2
- 125000004566 azetidin-1-yl group Chemical class N1(CCC1)* 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 230000001926 lymphatic Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000006431 methyl cyclopropyl group Chemical class 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 125000000999 tert-butyl group Chemical class [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 125000000250 methylamino group Chemical class [H]N(*)C([H])([H])[H] 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 102100019730 TP53 Human genes 0.000 description 31
- 101710026335 TP53 Proteins 0.000 description 31
- 102000002280 BRCA2 Protein Human genes 0.000 description 28
- 108010000750 BRCA2 Protein Proteins 0.000 description 28
- 102000036638 BRCA1 Human genes 0.000 description 26
- 108010042977 BRCA1 Protein Proteins 0.000 description 26
- 108060006202 ATM Proteins 0.000 description 20
- 102100000648 ATM Human genes 0.000 description 8
- 102000001170 RAD18 Human genes 0.000 description 7
- 108060007651 SMC6 Proteins 0.000 description 7
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 3
- 230000004777 loss-of-function mutation Effects 0.000 description 3
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 3
- 101700007241 APOC4 Proteins 0.000 description 2
- 101710038729 F2R Proteins 0.000 description 2
- 101700036247 PARP1 Proteins 0.000 description 2
- 102100014579 PARP1 Human genes 0.000 description 2
- 101700053624 PARP2 Proteins 0.000 description 2
- 101700027237 PROA Proteins 0.000 description 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 2
- 101700004528 arp Proteins 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000001404 mediated Effects 0.000 description 2
- 108020004999 Messenger RNA Proteins 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N Methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- 206010070308 Refractory cancer Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783014P | 2018-12-20 | 2018-12-20 | |
| US62/783,014 | 2018-12-20 | ||
| US201962799423P | 2019-01-31 | 2019-01-31 | |
| US62/799,423 | 2019-01-31 | ||
| US201962857986P | 2019-06-06 | 2019-06-06 | |
| US62/857,986 | 2019-06-06 | ||
| US201962868616P | 2019-06-28 | 2019-06-28 | |
| US62/868,616 | 2019-06-28 | ||
| US201962946263P | 2019-12-10 | 2019-12-10 | |
| US62/946,263 | 2019-12-10 | ||
| PCT/US2019/067521 WO2020132269A1 (en) | 2018-12-20 | 2019-12-19 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022511515A JP2022511515A (ja) | 2022-01-31 |
| JPWO2020132269A5 true JPWO2020132269A5 (pt) | 2022-12-26 |
Family
ID=71100912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531985A Pending JP2022511515A (ja) | 2018-12-20 | 2019-12-19 | 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤としてのそれらの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11485736B2 (pt) |
| EP (1) | EP3897652A4 (pt) |
| JP (1) | JP2022511515A (pt) |
| KR (1) | KR20210105887A (pt) |
| CN (1) | CN113164485A (pt) |
| AU (1) | AU2019405925A1 (pt) |
| BR (1) | BR112021010715A2 (pt) |
| CA (1) | CA3122108A1 (pt) |
| CL (1) | CL2021001575A1 (pt) |
| CO (1) | CO2021009078A2 (pt) |
| IL (1) | IL284050A (pt) |
| MX (1) | MX2021007179A (pt) |
| SG (1) | SG11202106232TA (pt) |
| WO (1) | WO2020132269A1 (pt) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3897652A4 (en) | 2018-12-20 | 2022-09-14 | KSQ Therapeutics, Inc. | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC TREATMENT PROTEASE 1 INHIBITORS |
| US20230065636A1 (en) * | 2020-01-15 | 2023-03-02 | KSQ Therapeutics, Inc. | Compositions of substituted pyrazolopyrimidines and uses thereof |
| MX2022009818A (es) * | 2020-02-14 | 2022-09-05 | Ksq Therapeutics Inc | Combinaciones terapeuticas que comprenden inhibidores de proteasa 1 de procesamiento especifico de ubiquitina (usp1) e inhibidores de poli (adp-ribosa) polimerasa (parp). |
| EP4161494A1 (en) * | 2020-06-02 | 2023-04-12 | KSQ Therapeutics, Inc. | Nitrogen-containing fused bicyclic compounds and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors |
| US11718624B2 (en) | 2020-10-30 | 2023-08-08 | KSQ Therapeutics, Inc. | Solid state forms of substituted pyrazolopyrimidines and uses thereof |
| WO2022174184A1 (en) * | 2021-02-15 | 2022-08-18 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
| IL305991A (en) * | 2021-03-17 | 2023-11-01 | Tango Therapeutics Inc | The history of purine as anticancer agents |
| AU2022254062A1 (en) * | 2021-04-07 | 2023-10-12 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 1 (usp1) |
| CA3217763A1 (en) * | 2021-05-03 | 2022-11-10 | Bin Liu | Tricyclic ubiquitin specific protease 1 inhibitor and use thereof |
| WO2022253188A1 (en) * | 2021-05-31 | 2022-12-08 | Impact Therapeutics (Shanghai) , Inc | Nitrogen-containing fused heteroaromatic bicyclic compounds as usp1 inhibitors and the use thereof |
| GB202114863D0 (en) | 2021-10-18 | 2021-12-01 | Syngenta Crop Protection Ag | Improvements in or relating to organic compounds |
| AU2022368823A1 (en) * | 2021-10-19 | 2024-05-16 | Impact Therapeutics (Shanghai), Inc. | Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof |
| CN114031556B (zh) * | 2021-11-08 | 2023-03-31 | 温州大学 | 一种绿色的一锅法制备5-氨基-n-芳基-3-芳基吡唑类化合物的合成方法 |
| AU2022387669A1 (en) * | 2021-11-12 | 2024-05-16 | Insilico Medicine Ip Limited | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| AR127646A1 (es) * | 2021-11-12 | 2024-02-14 | Insilico Medicine Ip Ltd | Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos |
| CN114181237B (zh) * | 2021-12-01 | 2024-02-23 | 上海凌凯医药科技有限公司 | 一种1-异丙基吡唑-5-硼酸频那醇酯的合成方法 |
| CA3237961A1 (en) * | 2021-12-09 | 2023-06-15 | Jeremy Clinton Wilt | Methods of preparing substituted pyrazolopyrimidines |
| WO2023143424A1 (zh) * | 2022-01-27 | 2023-08-03 | 四川海思科制药有限公司 | 一种氮杂并环衍生物及其在医药上的应用 |
| WO2023148643A1 (en) * | 2022-02-03 | 2023-08-10 | Aurigene Oncology Limited | Fused bicyclic heterocyclyl compounds as usp1 inhibitors |
| TW202342475A (zh) * | 2022-02-18 | 2023-11-01 | 大陸商四川海思科製藥有限公司 | 一種吡唑並吡啶衍生物及其在醫藥上的應用 |
| WO2023196955A1 (en) * | 2022-04-08 | 2023-10-12 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin- specific-processing protease 1 (usp1) inhibitors and chemotherapy agents |
| CN116496252A (zh) * | 2022-04-29 | 2023-07-28 | 江苏亚虹医药科技股份有限公司 | 嘧啶类化合物、其制备方法及其医药用途 |
| WO2023250084A1 (en) * | 2022-06-23 | 2023-12-28 | Forma Therapeutics, Inc. | Usp1 inhibitors and uses thereof |
| US20240092779A1 (en) * | 2022-06-29 | 2024-03-21 | Zentaur Therapeutics Usa Inc. | Usp1 inhibitors and uses thereof |
| WO2024022266A1 (en) * | 2022-07-25 | 2024-02-01 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heteroaryl compounds as inhibitors of usp1 |
| WO2024022519A1 (zh) * | 2022-07-28 | 2024-02-01 | 先声再明医药有限公司 | 杂环并嘧啶类化合物及其应用 |
| WO2024032647A1 (zh) * | 2022-08-09 | 2024-02-15 | 上海济煜医药科技有限公司 | 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途 |
| WO2024041634A1 (zh) * | 2022-08-26 | 2024-02-29 | 先声再明医药有限公司 | 三环类化合物及其应用 |
| WO2024046471A1 (zh) * | 2022-09-02 | 2024-03-07 | 上海齐鲁制药研究中心有限公司 | Usp1抑制剂 |
| WO2024051795A1 (zh) * | 2022-09-09 | 2024-03-14 | 正大天晴药业集团股份有限公司 | 用作泛素-特异性蛋白酶抑制剂的取代嘌呤酮衍生物 |
| WO2024061213A1 (zh) * | 2022-09-20 | 2024-03-28 | 正大天晴药业集团股份有限公司 | 用作泛素-特异性蛋白酶抑制剂的羰基稠合杂环衍生物 |
| WO2024078436A1 (zh) * | 2022-10-09 | 2024-04-18 | 海南先声再明医药股份有限公司 | 杂环并嘧啶类化合物、药物组合物及其应用 |
| WO2024086790A1 (en) | 2022-10-21 | 2024-04-25 | Exelixis, Inc. | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS |
| WO2024094170A1 (zh) * | 2022-11-04 | 2024-05-10 | 深圳晶泰科技有限公司 | 泛素特异性蛋白酶1的抑制剂及其应用 |
| CN116768906B (zh) * | 2023-05-29 | 2024-04-09 | 遵义医科大学珠海校区 | 一种三并环化合物及其制备方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| EP1695978A1 (en) | 1990-06-11 | 2006-08-30 | Gilead Sciences, Inc. | Nucleic acid ligands |
| AU672790B2 (en) | 1992-07-15 | 1996-10-17 | Novartis Ag | Variants of parathyroid hormone and its fragments |
| WO1996023899A1 (en) | 1995-02-01 | 1996-08-08 | University Of Massachusetts Medical Center | Methods of selecting a random peptide that binds to a target protein |
| DE69718341T2 (de) | 1996-10-08 | 2003-10-30 | Bisys B V U | Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
| US7754463B2 (en) | 2006-06-20 | 2010-07-13 | Dana-Farber Cancer Institute | Inhibitors of USP1 Deubiquitinating Enzyme Complex |
| JP2010506939A (ja) | 2006-10-20 | 2010-03-04 | ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド | ガンを処置するためのｄｎａ損傷修復阻害剤および方法 |
| US7964356B2 (en) | 2007-01-16 | 2011-06-21 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| RU2681081C2 (ru) | 2007-10-05 | 2019-03-04 | Верастэм, Инк. | Пиримидинзамещенные производные пурина, фармацевтическая композиция на их основе, способ ингибирования протеинкиназ, способ лечения или профилактики заболеваний, чувствительных к ингибированию протеинкиназ, и способ лечения пролиферативных заболеваний |
| WO2009111354A2 (en) * | 2008-03-03 | 2009-09-11 | Tiger Pharmatech | Tyrosine kinase inhibitors |
| WO2009157196A1 (ja) * | 2008-06-25 | 2009-12-30 | 武田薬品工業株式会社 | アミド化合物 |
| GB0917934D0 (en) * | 2009-10-13 | 2009-11-25 | Syngenta Ltd | Herbicidal compounds |
| US9518032B2 (en) * | 2010-04-30 | 2016-12-13 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of USP1 deubiquitinating enzyme activity |
| CA2896731A1 (en) | 2012-12-28 | 2014-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
| AU2014350051A1 (en) | 2013-11-18 | 2016-07-07 | Crispr Therapeutics Ag | CRISPR-Cas system materials and methods |
| KR101766194B1 (ko) * | 2015-08-07 | 2017-08-10 | 한국과학기술연구원 | RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물 |
| MX2021001186A (es) * | 2015-11-20 | 2022-10-11 | Forma Therapeutics Inc | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. |
| EP3897652A4 (en) | 2018-12-20 | 2022-09-14 | KSQ Therapeutics, Inc. | SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND THEIR USE AS UBIQUITIN-SPECIFIC TREATMENT PROTEASE 1 INHIBITORS |
| WO2022174184A1 (en) | 2021-02-15 | 2022-08-18 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
-
2019
- 2019-12-19 EP EP19897934.6A patent/EP3897652A4/en active Pending
- 2019-12-19 CA CA3122108A patent/CA3122108A1/en active Pending
- 2019-12-19 CN CN201980079551.2A patent/CN113164485A/zh active Pending
- 2019-12-19 BR BR112021010715A patent/BR112021010715A2/pt unknown
- 2019-12-19 AU AU2019405925A patent/AU2019405925A1/en active Pending
- 2019-12-19 SG SG11202106232TA patent/SG11202106232TA/en unknown
- 2019-12-19 MX MX2021007179A patent/MX2021007179A/es unknown
- 2019-12-19 WO PCT/US2019/067521 patent/WO2020132269A1/en unknown
- 2019-12-19 KR KR1020217017482A patent/KR20210105887A/ko unknown
- 2019-12-19 JP JP2021531985A patent/JP2022511515A/ja active Pending
- 2019-12-19 US US16/721,079 patent/US11485736B2/en active Active
-
2021
- 2021-06-15 IL IL284050A patent/IL284050A/en unknown
- 2021-06-16 CL CL2021001575A patent/CL2021001575A1/es unknown
- 2021-07-12 CO CONC2021/0009078A patent/CO2021009078A2/es unknown
-
2022
- 2022-10-11 US US18/045,770 patent/US11787813B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020132269A5 (pt) | ||
| Schenone et al. | Biologically driven synthesis of pyrazolo [3, 4-d] pyrimidines as protein kinase inhibitors: an old scaffold as a new tool for medicinal chemistry and chemical biology studies | |
| JP2022511515A (ja) | 置換されたピラゾロピリミジン及び置換されたプリンならびにユビキチン特異的プロセシングプロテアーゼ１（ｕｓｐ１）阻害剤としてのそれらの使用 | |
| KR20190046921A (ko) | 세포 대사 과정의 억제제 | |
| US11629147B2 (en) | Triazolo-pyrimidine compounds and uses thereof | |
| Abdellatif et al. | Pyrimidine and fused pyrimidine derivatives as promising protein kinase inhibitors for cancer treatment | |
| US8071581B2 (en) | Triazolopyridazine protein kinase modulators | |
| EP2084162B1 (en) | Bicyclic triazoles as protein kinase modulators | |
| TWI494314B (zh) | ５,７－取代的－咪唑并［１,２－ｃ］嘧啶 | |
| JP2020505454A5 (pt) | ||
| RU2019120986A (ru) | Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2 | |
| JP2013523884A5 (pt) | ||
| ES2391704T3 (es) | Inhibidores de cinasa AKT y P70 S6 | |
| RU2012152548A (ru) | Пиридоновые и азапиридоновые соединения и способы применения | |
| JP2017518326A5 (pt) | ||
| AU6178899A (en) | Method of treating nitrate-induced tolerance | |
| Rao et al. | An assessment study of known pyrazolopyrimidines: Chemical methodology and cellular activity | |
| EP4237086A1 (en) | Heterocyclic spiro compounds and methods of use | |
| JPWO2020231806A5 (pt) | ||
| US20230219965A1 (en) | Nitrogen-containing fused bicyclic compounds and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors | |
| US20240148732A1 (en) | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders | |
| JP2024023699A (ja) | 環式化合物およびその使用方法 | |
| JP7199737B2 (ja) | ピリジルピリドン化合物 | |
| RU2021114721A (ru) | Замещенные пиразолопиримидины и замещенные пурины и их применение в качестве ингибиторов убиквитин-специфической процессирующей протеазы 1 (usp1) | |
| JPWO2021021986A5 (pt) |